1st european appoval for a gene therapy drug

The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended, last Friday, the authorisation of Glybera (alipogene tiparvovec) for marketing in the European Union. For Fulvio Mavilio, Genethon CSO, that’s “great news for the gene therapy field".

Glybera is a treatment for patients who cannot produce enough of an enzyme that is crucial for breaking down fat. Glybera uses a virus that is injected into the patient to deliver a working copy of a gene for producing lipoprotein lipase (LPL). LPL deficiency is very rare, affecting no more than one or two people in every million.

Learn more about the first european approval for a gene therapy

http://www.leoy.net http://blog.kitapindirim.com http://www.richpac.org http://www.thesole.org http://iyinet2012seoyarismasillhtnbsklhyktr.eu universidade do turkey

05 Jan 2022

First-ever United Nations resolution to increase visibility for persons living with a rare disease and their families

On 16 December 2021, the UN adopted the first-ever UN Resolution on “Addressing the Challenges of Persons Living with a Rare Disease and their Families.” A huge recognition for families with rare diseases.

22 Dec 2021

Myology 2022 and MitoNice 2022: registration and abstract submission are open

From September 12 to 17, 2022, AFM-Telethon will hold two international scientific congresses at the Nice Acropolis Convention Centre. You can already submit your work to participate.

20 Dec 2021

€ 73 622 019 thank you! The fight can continue!

The 2021 Telethon ended with donations totaling 73 622 019 euros. An amount reflecting the generosity of the general public, the energy felt during thousands of Telethon events throughout France and abroad, and the strength of families’ fight and researchers’ determination. This unique combination is the cause for a true revolution in medicine that saves lives and opens up new prospects for treatment.

All the news